Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941803 | 0.92 | MAPT (0.56) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL9581284 | 0.84 | MAPT (0.56) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4746770 | 0.81 | MEN1 (0.63) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL853676 | 0.81 | MEN1 (0.65) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL16322249 | 0.80 | MEN1 (0.61) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL1429699 | 0.78 | MEN1 (0.65) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL855050 | 0.77 | MAPT (0.66) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2941831 | 0.76 | HTT (0.59) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL23748585 | 0.76 | MEN1 (0.70) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL9018657 | 0.76 | MEN1 (0.71) | MAPTALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| EP-1720844-B1 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | CEZANNE BERTRAM | 2008-04-03 | — | — | US | disclosed |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | CEZANNE BERTRAM | 2008-04-03 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| WO-2006034789-A1 | PROLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006034769-A1 | CARBONYL COMPOUNDS USABLE AS COAGULATION FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006032342-A2 | CARBONYL COMPOUND-CONTAINING DRUG AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265259-A1 | Proline Derivatives | F2, XPNPEP1, PRAP1 | MAPT 4809/4885ALDH1A1 1828/4885POLB 3690/4885 |
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | MAPT 3896/4885ALDH1A1 268/4885POLB 2957/4885 |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | F2, F11, F12 | MAPT 4368/4885ALDH1A1 593/4885POLB 3312/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | MAPT 2660/4885ALDH1A1 339/4885POLB 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.